CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.16th October 2023
From disease modification to disease resolution
Disease resolution is possible.
While conventional disease-modifying medicines can slow pathologic, symptomatic and functional decline, they cannot reverse disease and may suppress repair. Our approach has the potential to go beyond conventional disease modification by rebuilding damaged tissue to restore normal architecture. This could enable patients to not only reduce symptoms but also reverse their decline, resolving disease and regaining lost function.
Our groundbreaking products program disease resolution and offer novel treatments for a wide range of disorders. Our lead asset is in development for autoimmunity and fibrosis.
Our pipeline consists of programmed disease-resolving drugs, offering novel treatments for a wide range of disorders.
"It’s hard to imagine anything more rewarding than translating exciting science into treatments with the potential to benefit patients."
CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.17th August 2023